Disruptive innovation is a priority for anyone seeking growth in today’s investment climate. Milltrust clients receive privileged access to thoroughly vetted opportunities across a range of risk/return profiles.
Despite British universities being consistently high in global rankings, Britain has historically struggled to raise sufficient capital to commercialise its world-class research. The British Innovation Fund supplies capital to support early stage spin out companies forming as a result of this research. The Fund invests into leading British University spinout companies emanating from these Universities.
The British Innovation Fund recognises the world-class science and technology development that is being carried out in many of Britain’s top universities. The Fund nurtures impactful, early-stage companies – helping them reach their full potential and guiding them to world-wide recognition and success.
The Fund carefully picks spinout companies from its network of universities as well as the established, in-house university commercialisation companies which the Fund is in close contact with – spinout companies that demonstrate a viable commercial business, have unique patented IP and have technology with platform capability. This significantly reduces investment risks and enhances the probability of outsized returns for investors.
1. Academics bring promising IP and commercially reliable ideas to the attention of university technology transfer offices (“TTO”) and university commercialisation companies
2. TTOs provide funding and support to the most promising opportunities which are spun out as individual companies, with further investment from the experienced technologists and venture capitalist at the university commercialisation companies
3. Investment opportunities are shared with the team at the British Innovation Fund through their relationships with TTOs and the commercialisation companies
4. Enhanced due diligence, including scientific validation from specialists and review by the investment advisory committee, is conducted prior to deployment of capital from the British Innovation Fund.
A spinout of Oxford University, Vaccitech’s immunotherapy and vaccine platform utilises IP developed at Oxford University’s prestigious Jenner Institute to generate product candidates for infectious disease and cancer indications. Vaccitech’s technology was instrumental in the development of the Oxford / AstraZeneca Covid-19 vaccine.
AMLo is an innovative medical device company that specialises in the early detection of skin cancers with metastatic potential. Spun out of Newcastle University, AMLo’s goal is to improve mortality rates from cancers arising from previously undetected high-risk lesions, enabling targeted and personalised cancer management.
PragmatIC, backed by Cambridge Innovation Capital, is a world leader in the manufacturing of ultra low cost flexible electronics, enabling the potential for trillions of smart objects that can engage with consumers and their environments. PragmatIC’s unique technology platform delivers flexible integrated circuits that are thinner than a human hair and can be easily embedded into everyday objects.View Video
Attomarker, a spin out from the University of Exeter, is a digital health technology company which has developed a small, simple-to-use blood-testing device that can perform blood tests from a single pin-prick of blood, with results in around five minutes. This multi-patented technology collects the blood sample on a disposable credit-card sized chip which slots into a fully mobile device, docked to an iPhone. The iPhone camera visualises the blood tests which are then interpreted by the iPhone.View Video
Oxford Sciences Innovation (OSI) is the commercialisation partner of Oxford University’s sciences departments. Its vision is to turn a thousand years of world-beating science into the next generation of world-leading companies by linking Oxford’s research to the best human and financial capital.Learn More
Roslin Technologies is the technology commercialisation company of the University of Edinburgh’s Roslin Institute. Based at Easter Bush Campus, the largest concentration of animal science expertise in Europe, Roslin Technologies exists to deliver breakthrough commercial solutions in the Animal Health, Breeding/Genetics and Animal Nutrition space based on the expert agricultural research of the Institute.View Video
The British Innovation Fund actively seeks to maximize its alignment to the UN Sustainable Development Goals (SDGs), which were adopted by all United Nations Member States in 2015 as a universal call to action to end poverty, protect the planet and ensure that all people enjoy peace and prosperity by 2030. Achieving the SDGs requires the partnership of governments, private sector, civil society and citizens alike to make sure we leave a better planet for future generations. The fund’s primary SDG alignment focus is on:
End hunger, achieve food security and improved nutrition and promote sustainable agriculture.
Ensure healthy lives and promote well-being for all at all ages.
Ensure access to affordable, reliable, sustainable and modern energy for all.
Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation.
Ensure sustainable consumption and production patterns.
Take urgent action to combat climate change and its impacts.
Conserve and sustainably use the oceans, seas and marine resources for sustainable development.
Protect, restore and promote sustainable use of terrestrial ecosystems, sustainably manage forests, combat desertification, and halt and reverse land degradation and halt biodiversity loss.
|Platform:||Milltrust International Managed Investments ICAV|
|Investment Manager:||Milltrust International LLP|
|Investment Adviser:||Milltrust Agricultural Investments Ltd|
|Structure:||Open-ended Investment Company|
|Strategy:||Commercialisation of research emerging out of UK universities|
|Inception Date:||25 November 2016|
|Share Classes:||Class (A), Class (B), Class (C), Class (D)|
|Performance Fee:||20% over Hurdle Rate|
|Subscription Terms:||10 years|
|Investor Types:||For Professional and Accredited Investors Only|
|Registered for Distribution in:||United Kingdom, Ireland|
|Administrator:||MUFG Alternative Fund Services (Ireland) Ltd.|
|Custodian:||Mitsubishi UFJ Investor Services & Banking (Luxembourg) S.A.|
MILLTRUST INTERNATIONAL MANAGED INVESTMENTS ICAV
Milltrust International Group
CEO & CIO
MILLTRUST AGRICULTURAL INVESTMENTS
MEMBER OF THE Investment Advisory Committee
BRITISH INNOVATION FUND
Member of the Investment Advisory Committee
British Innovation Fund
CerraCap II SP is a Global fund dedicated to early-stage technology investments. The fund focuses on Enterprise (B2B) products and solutions in the emerging technology areas of Healthcare, AI and Cyber Security.
The fund reduces investment risk by maintaining one strategy since inception; targeting great teams with high growth characteristics. CerraCap makes great management better by personally introducing companies to Fortune 500 decision-makers. The team calls this model Sales and Scale where they industrialize innovation.
CerraCap II SP is a sub-fund of CerraCap International Investments SPC, registered in the Cayman Islands, and is managed by Epithauma LLC. The fund is a feeder into a US master fund, Cerracap II LP.
The team has worked together for an average of 10yrs. They have achieved over $500M in combined software sales and previously ran a highly successful corporate VC for a large tech company
Help sell portfolio companies into Fortune 500 enterprises. De-risking the early-stage model
“Enable Purchase Orders, not just introductions”
Collaboration with IT companies Fortune 500 clients and larger VCs
Unparalleled and ACTIVE Advisory board; providing leverage and access
GPs have 52 investments over seven years
Average valuation multiple across previous investments 9x
Dathena is the first data governance platform developed by real users for real users. Dathena's mission is to transform data from a liability to an asset. Dathena was built with state-of-the-art technologies including machine learning and artificial intelligence capabilities.Learn More
Founded in 2017 with focus on developing NLP+AI driven cognitive products for Enterprises. Developing AI based Natural Language Understanding and Automated Content Generation Platform. AutoR.ai is Nirveda’s 1st Authoring Assistant that helps content creators generate original content. Currently working in Stealth mode with one of world’s largest asset management company.View Video
In Quantix, Cerracap has assembled a powerhouse team with the ability, experience and the means to solve one of the most complex problems in the financial markets. Quantix has a singular focus: to build the most advanced commodity trading platform of its kind that analyzes more sources and types of data (social media, satellite images, real time news sources etc) and generates the most accurate predictions on price and volatility than anything else in the market. Sharpening The Competitive Edge For Commodities Traders, Quantix Processes Over 1200 Structured And Unstructured Parameters To Design Unbiased Trading Strategies In Real Time.Learn More
Censia is a people-obsessed company that believes talent is an organization’s most valuable asset. They exist to deliver the best talent to enterprises in the most efficient way possible through the power of intelligent technology. They’re transforming talent acquisition into a strategic partner that shapes the future of the company.Learn More
Deep Instinct is the first company to apply deep learning to cybersecurity. Harnessing the power of deep learning’s predictive capabilities in order to create the ultimate cyber security solution: On- device, proactive solution that protects against zero-day threats and APT attacks with unmatched accuracy. Deep Instinct provides comprehensive defense that is designed to protect against the most evasive unknown malware in real- time, across an organization’s endpoints, servers, and mobile devices. Leveraging deep learning’s capabilities of identifying malware from any data source results in total protection: Any threat. Anywhere. Any time.Learn More
Based on patented deep learning models, Agshift autonomously inspects produce and other commodities for defects. It does quality assessments and makes judgements as per USDA specifications or your organization's quality requirements. Agshift’ s solution delivers the biggest impact on reducing global food wasteLearn More
Viome is focused on disrupting healthcare by “making illness optional”. The Viome test is a breakthrough microbiome bacteria, epigenetics, epigenome and epigenomics technology. Chronic diseases are the fastest growing diseases all over the world. Viome has the potential to positively impact millions of people if not billions all around the world. Driven to create a future where illness is optional by identifying predictive biomarkers for diseases before any symptoms may occur so they can be prevented. The goal is to responsibly present facts in a way that can help anyone make decision. By applying Artificial Intelligence to the massive amount of high resolution microbiome and genetic data to find predictive biomarkers for chronic diseases.Learn More
The fund is managed by CerraCap Ventures, headquartered in California with operations out of global hubs of tech innovation (San Francisco, Tel Aviv, and Bangalore).
The team at CerraCap Ventures are former UST Global execs from California, with a past track record returning a stellar 9x return since inception.
CerraCap Ventures also boasts a phenomenal advisory board including Vicente Fox, former President of Mexico, John C. Cushman, Chairman of Cushman & Wakefield, Richard P Crane Jr., Lawyer and Member of U.S. Department of Justice, and our own Simon Hopkins, amongst others
The offering documents for the Milltrust International Managed Investments ICAV are only available to residents of the European Union, as follows:
1. To persons who qualify as a “Professional client” in accordance with Annex II of the Directive 2014/65/EU (Markets in Financial Instruments Directive), as may be amended, replaced, supplemented or novated.
The following qualify as professional clients:
· Entities which are required to be authorised or regulated to operate in the financial markets:
(a) Credit institutions
(b) Investment firms
(c) Other authorised or regulated financial institutions
(d) Insurance companies
(e) Collective investment schemes and management companies of such schemes
(f) Pension funds and management companies of such funds
(g) Commodity and commodity derivatives dealers
(h) Other institutional investors
· Large undertakings meeting two of the following size requirements on a company basis:
(a) balance sheet total: EUR 20 000 000
(b) net turnover: EUR 40 000 000
(c) own funds: EUR 2 000 000
· National and regional governments, public bodies that manage public debt, Central Banks, international and supranational institutions such as the World Bank, the IMF, the ECB, the EIB and other similar international organisations.
· Other institutional investors whose main activity is to invest in financial instruments.
I/We hereby certify that I/we am/are a professional client as defined above.
2. To persons who have received an appraisal from an EU credit institution, a MiFID firm or a UCITS management company that they have the appropriate expertise, experience and knowledge to adequately understand the potential investment in the Milltrust International Managed Investments ICAV.
I/We hereby certify that I/we am/are an investor who has received an appraisal as set out above.
I/We hereby indemnify and hold harmless Milltrust International Managed Investments ICAV, Milltrust International LLP, any other member of the group of entities owned by Milltrust International Group (Singapore) Pte. Ltd. and their respective directors, members, partners, agents, officers and anyone acting on their behalf from and against all damages, losses, costs and expenses (including, without limitation, reasonable attorneys’ fees) which they may incur by reason of any material breach of the above representations and warranties made by me/us.